Aβ peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons

Brain Research

Volumn 1142, Issue 1, 2007, Pages 223-236

  Clifford, Peter M ^a   Zarrabi, Shabnam ^a   Siu, Gilbert ^a   Kinsler, Kristin J ^a   Kosciuk, Mary C ^a   Venkataraman, Venkateswar ^b   D'Andrea, Michael R ^c   Dinsmore, Steven ^a   Nagele, Robert G ^a  

^a UMDNJ School of Osteopathic Medicine   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

A 42; Alzheimer's disease; Amyloid; Blood brain barrier; Neuron; Pertussis toxin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLUORESCEIN ISOTHIOCYANATE; PERTUSSIS TOXIN; SODIUM CHLORIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; COLLAGEN TYPE 4; DIAGNOSTIC AGENT; INDOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOPLASM; DENTATE GYRUS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; PYRAMIDAL NERVE CELL; AGED; ANIMAL; BRAIN; CADAVER; CAPILLARY PERMEABILITY; CASE CONTROL STUDY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

MUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; COLLAGEN TYPE IV; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDOLES; MICE; NEURONS; PERTUSSIS TOXIN; POSTMORTEM CHANGES; PROTEIN TRANSPORT; TIME FACTORS;

EID: 33947164189     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.01.070     Document Type: Article

References (88)

1. Amiel S.A. The effects of Bordetella pertussis vaccine on cerebral vascular permeability. Br. J. Exp. Pathol. 57 (1976) 653-662
2. Andreasen N., and Blennow K. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 23 (2002) 1205-1214
3. Bailey T.L., et al. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol. Res. 26 (2004) 573-578
4. Banerjee C., et al. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease-A stereological approach. Neurobiol. Dis. 7 (2000) 666-672
5. Ben-Nun A., et al. Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer. Proc. Assoc. Am. Physicians 109 (1997) 120-125
6. Braak H., and Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1 (1991) 213-216
7. Breese C.R., et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J. Comp. Neurol. 387 (1997) 385-398
8. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 21 (2000) 153-160
9. Bruckener K.E., et al. Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J. Cell Sci. 116 (2003) 1837-1846
10. Buee L., et al. Brain microvascular changes in Alzheimer's disease and other dementias. Ann. N. Y. Acad. Sci. 826 (1997) 7-24
11. Burghaus L., et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res. Mol. Brain Res. 76 (2000) 385-388
12. Chang K.T., and Berg D.K. Nicotinic acetylcholine receptors containing alpha7 subunits are required for reliable synaptic transmission in situ. J. Neurosci. 19 (1999) 3701-3710
13. Citron M., et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11993-11997
14. Cohen M.L., et al. In situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 1227-1231
15. D'Andrea M.R., and Nagele R.G. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Des. 12 (2006) 677-684
16. D'Andrea M.R., et al. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38 (2001) 120-134
17. Deane R., et al. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35 (2004) 2628-2631
18. De Felice F.G., and Ferreira S.T. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol. 22 (2002) 545-563
19. de la Torre J.C. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826 (1997) 75-91
20. de la Torre J.C. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol. Res. 26 (2004) 517-524
21. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3 (2004) 184-190
22. Dickson D.W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 18 (1997) S21-S26
23. Esiri M.M., et al. Neuropathological assessment of the lesions of significance in vascular dementia. J. Neurol., Neurosurg. Psychiatry 63 (1997) 749-753
24. Esiri M.M., et al. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354 (1999) 919-920
25. Farkas E., and Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64 (2001) 575-611
26. Felician O., and Sandson T.A. The neurobiology and pharmacotherapy of Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 11 (1999) 19-31
27. Ghiso J., et al. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett. 408 (1997) 105-108
28. Gloor S.M., et al. Molecular and cellular permeability control at the blood-brain barrier. Brain Res. Brain Res. Rev. 36 (2001) 258-264
29. Gomez-Isla T., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41 (1997) 17-24
30. Greenberg S.M. Small vessels, big problems. N. Engl. J. Med. 354 (2006) 1451-1453
31. Guan Z.Z., et al. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 74 (2000) 237-243
32. Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12 (1991) 383-388
33. Hebert L.E., et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
34. Hellstrom-Lindahl E., et al. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 66 (1999) 94-103
35. Higgins G.A., et al. Altered levels of amyloid protein precursor transcripts in the basal forebrain of behaviorally impaired aged rats. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 3032-3036
36. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 109 (2002) 813-836
37. Kalaria R.N. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol. Ther. 72 (1996) 193-214
38. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21 (2000) 321-330
39. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13 Suppl. 2 (2002) 48-52
40. Kalaria R.N., et al. Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Brain Res. Mol. Brain Res. 35 (1996) 58-68
41. Kandimalla K.K., et al. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313 (2005) 1370-1378
42. Kasa P., et al. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52 (1997) 511-535
43. Koo E.H., and Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269 (1994) 17386-17389
44. Lee D.H.-S., et al. Decreased alpha-7 nicotinic acetylcholine receptor protein levels in sporadic Alzheimer's disease hippocampus. Alzheimer's Rep. 3 (2000) 215-218
45. Linthicum D.S., et al. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73 (1982) 299-310
46. Liu Q., et al. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4734-4739
47. Mackic J.B., et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul. Pharmacol. 38 (2002) 303-313
48. Maness L.M., et al. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci. 55 (1994) 1643-1650
49. Masters C.L., et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985) 2757-2763
50. Mayeux R., et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
51. Mayhan W.G. Regulation of blood-brain barrier permeability. Microcirculation 8 (2001) 89-104
52. Mirra S.S., et al. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch. Pathol. Lab. Med. 117 (1993) 132-144
53. Nagele R.G., et al. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110 (2002) 199-211
54. Nagele R.G., et al. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971 (2003) 197-209
55. Nalivaevaa N.N., et al. Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Ann. N. Y. Acad. Sci. 1035 (2004) 21-33
56. Natte R., et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 29 (1998) 1588-1594
57. Nordberg A. Human nicotinic receptors-Their role in aging and dementia. Neurochem. Int. 25 (1994) 93-97
58. Paterson D., and Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61 (2000) 75-111
59. Pettit D.L., et al. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21 (2001) RC120
60. Poduslo J.F., et al. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol. Dis. 4 (1997) 27-34
61. Poduslo J.F., et al. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6 (1999) 190-199
62. Risau W., et al. Differentiation of blood-brain barrier endothelial cells. Pathol. Biol. (Paris) 46 (1998) 171-175
63. Scott S.A., et al. Volumetric atrophy of the amygdala in Alzheimer's disease: quantitative serial reconstruction. Neurology 41 (1991) 351-356
64. Seguela P., et al. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13 (1993) 596-604
65. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271 (1996) 18295-18298
66. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
67. Seubert P., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
68. Shayo M., et al. The putative blood-brain barrier transporter for the beta-amyloid binding protein apolipoprotein j is saturated at physiological concentrations. Life Sci. 60 (1997) L115-L118
69. Skoog I., et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 50 (1998) 966-971
70. Strittmatter W.J., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8098-8102
71. Teller J.K., et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2 (1996) 93-95
72. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18 (1997) S1-S2
73. Ujiie M., et al. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10 (2003) 463-470
74. Ullian E.M., et al. Rapid synaptic transmission in the avian ciliary ganglion is mediated by two distinct classes of nicotinic receptors. J. Neurosci. 17 (1997) 7210-7219
75. Wada H. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern. Med. 37 (1998) 509-513
76. Wang H.Y., et al. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275 (2000) 5626-5632
77. Wen Y., et al. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 1009 (2004) 1-8
78. Wevers A., and Schroder H. Nicotinic acetylcholine receptors in Alzheimer's disease. J. Alzheimer's Dis. 1 (1999) 207-219
79. Wevers A., et al. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav. Brain Res. 113 (2000) 207-215
80. Whitehouse P.J., and Kalaria R.N. Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. Alzheimer Dis. Assoc. Disord. 9 Suppl. 2 (1995) 3-5
81. Wilson C.A., et al. Intracellular APP processing and A beta production in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58 (1999) 787-794
82. Wisniewski H.M., and Wen G.Y. Substructures of paired helical filaments from Alzheimer's disease neurofibrillary tangles. Acta Neuropathol. (Berl.) 66 (1985) 173-176
83. Wisniewski H.M., et al. Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826 (1997) 161-172
84. Yong T., et al. Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice. J. Neuroimmunol. 45 (1993) 47-52
85. Zagorski M.G., et al. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol. 309 (1999) 189-204
86. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89 (2004) 807-811
87. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208
88. Zlokovic B.V., et al. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun. 197 (1993) 1034-1040